Rhythm Beats Q1, Analysts Raise Targets; Core Thesis Unchanged

What happened

Rhythm Pharmaceuticals reported better-than-expected first-quarter financial results on Tuesday, beating revenue expectations and narrowing losses. Analysts responded by raising price targets, citing strong IMCIVREE sales and growing optimism around the upcoming hypothalamic obesity (HO) launch. The Q1 beat modestly reduces near-term execution risk but does not alter the core investment thesis: the stock remains fully valued at ~45x book with no earnings-based margin of safety. Sustained profitability depends entirely on a successful HO launch and disciplined expense control, both of which are unproven. Investors should focus on HO patient starts and SG&A growth rather than react to the post-earnings momentum.

Implication

The Q1 results validate the base case but do not change the fundamental risk-reward; the position should remain a wait until HO launch metrics (patient starts, payer coverage) and expense discipline are clearer, with an attractive entry near $80 or after demonstrable traction.

Thesis delta

The Q1 beat modestly supports the base case (45% probability) and reduces near-term cash-burn concerns, but it does not address the binary nature of the HO launch outcome or the high expense growth; the thesis remains in wait mode pending HO execution evidence.